Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Translational Neuroscience

Editor-in-Chief: David, Olivier


IMPACT FACTOR 2018: 2.038

CiteScore 2018: 1.90

SCImago Journal Rank (SJR) 2018: 0.665
Source Normalized Impact per Paper (SNIP) 2018: 0.786

Open Access
Online
ISSN
2081-6936
See all formats and pricing
More options …

Translati onal challenges of neuroprotection strategy in ischemic stroke

Hrvoje Budincevic / Ivan Bielen / Laszlo Csiba
  • Department of neurology, University of Debrecen, Medical and Health Science Center, Nagyerdei Körút 98, P.O. Box 48, Debrecen, Hungary
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2011-12-28 | DOI: https://doi.org/10.2478/s13380-011-0041-2

Abstract

Neuroprotection is a therapeutic strategy that attempts to save neurons from irreversible injury by modifying the effects of the ischemic cascade or facilitating reperfusion. Although numerous agents have shown neuroprotective effect in preclinical trials, their translation to clinical trials failed to show any meaningful effect. The Stroke Therapy Academic Industry Roundtable (STAIR) guidelines were made for performing research on neuroprotective agents in pre-clinical and clinical trials. Although the STAIR guidelines have been available for more than ten years, we still do not have any adequate neuroprotective agents. Reasons for unsuccessful translation from preclinical to clinical research can be considered along stages of drug development: 1) preclinical, 2) transitional and 3) clinical. By extending the therapeutic window for application of intravenous thrombolysis in acute stroke patients to 4.5 hours, as well as increasing the use intra-arterial thrombolysis and development of mechanical devices for thrombectomy in 6 hour period we may be able to achieve some degree of neuroprotection in acute stroke. Future therapy is likely to add to the current thrombolytic therapy with potential neuroprotective drugs or procedures.

Keywords: Ischemic stroke; Neuroprotection; Translational problems

  • [1] Lloyd-Jones D., Adams R., Carnethon M., De Simone G., Ferguson T. B., Flegal K. et al., Heart disease and stroke statistics — 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Circulation, 2009, 119, e21–181 http://dx.doi.org/10.1161/CIRCULATIONAHA.108.191261CrossrefGoogle Scholar

  • [2] Diedler J., Sykora M., Jüttler E., Steiner T., Hacke W., Intensive care management of acute stroke: general management, Int. J. Stroke, 2009, 4, 365–378 http://dx.doi.org/10.1111/j.1747-4949.2009.00338.xCrossrefGoogle Scholar

  • [3] Rundek T., Sacco R. L., Demarin V., Neuroprotection in Acute stroke: Is there still hope, Acta Clin. Croat., 2002, 41, 45–49 Google Scholar

  • [4] Shiber J. R., Fontane E., Adewale A., Stroke registry: hemorrhagic vs ischemic strokes, Am. J. Emerg. Med., 2010, 28, 331–333 http://dx.doi.org/10.1016/j.ajem.2008.10.026CrossrefGoogle Scholar

  • [5] Adams H. P. Jr., Bendixen B. H., Kappelle L. J., Biller J., Love B. B., Gordon D. L. et al., Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment, Stroke, 1993, 24, 35–41 http://dx.doi.org/10.1161/01.STR.24.1.35CrossrefGoogle Scholar

  • [6] Ginsberg M D., Current status of neuroprotection for cerebral ischemia synoptic overview, Stroke, 2009, 40(Suppl. 3), S111–114 http://dx.doi.org/10.1161/STROKEAHA.108.528877CrossrefGoogle Scholar

  • [7] Green A. R., Protecting the brain: the search for a clinically effective neuroprotective drug for stroke, Crit. Rev. Neurobiol., 1990, 16, 91–97 http://dx.doi.org/10.1615/CritRevNeurobiol.v16.i12.100CrossrefGoogle Scholar

  • [8] Budinčević H., Jurlina H., Bielen I., Neuroprotection in ischemic stroke, Neurol. Croat., 2010, 59, 127–137 Google Scholar

  • [9] Cheng Y. D., Al-Khoury L., Zivin J. A., Neuroprotection for ischemic stroke: Two decades of Success and Failure, NeuroRx, 2004, 1, 36–45 http://dx.doi.org/10.1602/neurorx.1.1.36CrossrefGoogle Scholar

  • [10] The National Instutute of Neurological Disorders and Stroke rt-PA Stroke Study Group, Tissue plasminogen activator for acute stroke, N. Engl. J. Med., 333, 1581–1587 Google Scholar

  • [11] Young A. R., Ali C., Duretete A., Vivien D., Neuroprotection and stroke: time for a compromise, J. Neurochem., 2007, 103, 1302–1309 http://dx.doi.org/10.1111/j.1471-4159.2007.04866.xCrossrefGoogle Scholar

  • [12] European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee, Guidelines for management of ischaemic stroke and transient ischaemic attack 2008, Cerebrovasc. Dis., 2008, 25, 457–507 http://dx.doi.org/10.1159/000131083CrossrefGoogle Scholar

  • [13] Albers G. W., Atkinson R. P., Kelley R. E., Rosenbaum D.M., Safety, tolerability and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrophan in patients with acute stroke. Dextrophan Study Group, Stroke, 1995, 26, 254–258 CrossrefGoogle Scholar

  • [14] Faden A. I., Stoica B., Neuroprotection: challenges and opportunities, Arch. Neurol., 2007, 64, 794–800 http://dx.doi.org/10.1001/archneur.64.6.794CrossrefGoogle Scholar

  • [15] Ginsberg M. D., Neuroprotection for ischemic stroke: Past, present and future, Neuropharmacology, 2008, 55, 363–389 http://dx.doi.org/10.1016/j.neuropharm.2007.12.007CrossrefGoogle Scholar

  • [16] Yakovlev A. G., Faden A. I., Mechanisms of neuronal cell death:implications for development of neuroprotective treatment strategies, NeuroRx, 2004, 1, 5–16 http://dx.doi.org/10.1602/neurorx.1.1.5CrossrefGoogle Scholar

  • [17] O’Collins V. E., Macleod M. R., Donnan G. A., Horky L. L., van der Worp B. H., Howells D. W., 1026 experimental treatments in acute stroke, Ann. Neurol., 59, 467–477 Google Scholar

  • [18] Fisher M., Neuroprotection of acute ischemic stroke: Where are we?, Neuroscientist, 1999, 5, 392–401 Google Scholar

  • [19] Fisher M., Feuerstein G., Howells D. W., Hurn P. D., Kent T. A., Savitz S. I. et al., Update of the stroke therapy academic industry roundtable preclinical recommendations, Stroke, 2009, 40, 2244–2250 http://dx.doi.org/10.1161/STROKEAHA.108.541128CrossrefGoogle Scholar

  • [20] Stroke Therapy Academic Industry Roundtable II (STAIR-II). Recommendations for clinical trial evaluation of acute stroke therapies, Stroke, 2001, 32, 1598–1606 http://dx.doi.org/10.1161/01.STR.32.7.1598CrossrefGoogle Scholar

  • [21] Stroke Therapy Academic Industry Roundtable. Recommendations for standards regarding preclinical neuroprotective and restorative dug development, Stroke, 1999, 30, 2752–2758 http://dx.doi.org/10.1161/01.STR.30.12.2752CrossrefGoogle Scholar

  • [22] Astrup J., Siesjö B. K., Symon L., Thresholds in cerebral ischemia — the ischemic penumbra, Stroke, 1981, 12, 723–725 http://dx.doi.org/10.1161/01.STR.12.6.723CrossrefGoogle Scholar

  • [23] Sharp F. R., Swanson R. A., Honkaniemi J., Kogure K., Massa S. M., Neurochemistry and molecular biology. In: Barnett HJM, Mohr JP, Stein BM, Yatsu FM, eds. Stroke: pathophysiology, diagnosis and management. 3rd ed., New York: Churchill Livingstone, 1998, 51–83 Google Scholar

  • [24] Hallenbeck J. M., Dutka A.J., Background review and current concepts of reperfusional injury, Arch. Neurol., 1990, 47, 1245–1254 http://dx.doi.org/10.1001/archneur.1990.00530110107027CrossrefGoogle Scholar

  • [25] D’Ambrosio A. L., Pinsky D. J., Connolly E.S., The role of the complement cascade in ischemia/reperfusion injury: implications for neuroprotection, Mol. Med., 2001, 7, 367–382 Google Scholar

  • [26] Lakhan S. E., Kirchgessner A., Hofer M., Inflammatory mechanisms in ischemic stroke: therapeutic approaches, J. Transl. Med., 2009, 7, 97 http://dx.doi.org/10.1186/1479-5876-7-97CrossrefGoogle Scholar

  • [27] Woolsey T. A., Rovainen C. M., Cox S. B., Henegar M. H., Liang G. E., Liu D. Q.et al., Neuronal units linked to microvascular modules in cerebral cortex: Response elements for imaging the brain, Cereb. Cortex, 1996, 6, 647–660 http://dx.doi.org/10.1093/cercor/6.5.647CrossrefGoogle Scholar

  • [28] Macrae I. M., Preclinical stroke research—advantages and disadvantages of the most common rodent models of focal ischaemia, Br. J. Pharmacol., 2011, 164, 1062–1078 http://dx.doi.org/10.1111/j.1476-5381.2011.01398.xCrossrefGoogle Scholar

  • [29] Woodruff T. M., Thundyil J., Tang S. C., Sobey C. G., Taylor S. M., Arumugam T. V., Pathophysiology, treatment and animal and cellular models of human ischemic stroke, Mol. Neurodegener., 2011, 25,6, 11 http://dx.doi.org/10.1186/1750-1326-6-11CrossrefGoogle Scholar

  • [30] Csiba L., Bereczki D., Shima T., Okada Y., Yamane K., Yamada T. et al, Acta Neurochir., 1992, 114, 51–58 http://dx.doi.org/10.1007/BF01401114CrossrefGoogle Scholar

  • [31] Molnár L., Hegedüs K., Fekete I., Reversible experimental middle cerebral artery occlusion, Stroke, 1990, 21, 679–680 http://dx.doi.org/10.1161/01.STR.21.4.679CrossrefGoogle Scholar

  • [32] Bederson J. B., Pitts L. H., Tsuji M., Nishimura M. C., Davis R. L., Bartkowski H., Rat middle cerebral-artery occlusion — evaluation of the model and development of a neurologic examination, Stroke, 1986, 17, 472–476 http://dx.doi.org/10.1161/01.STR.17.3.472CrossrefGoogle Scholar

  • [33] Li Y., Chopp M., Chen J. L., Wang L., Gautam S. C., Xu S. et al., Intrastriatal transplantation of bone marrow nonhematopoietic cells improves functional recovery after stroke in adult mice, J. Cereb. Blood Flow Metabol., 2000, 20, 1311–1319 http://dx.doi.org/10.1097/00004647-200009000-00006CrossrefGoogle Scholar

  • [34] Weinberger J. M., Evolving therapeutic approaches to treating acute ischemic stroke, J. Neurol. Sci., 2006, 249, 101–109 http://dx.doi.org/10.1016/j.jns.2006.06.010CrossrefGoogle Scholar

  • [35] Schwabitz W. R., Fisher M., Perspectives on neuroprotective stroke therapy, Biochem. Soc. Trans., 2006, 34, 1271–1276 http://dx.doi.org/10.1042/BST0341271CrossrefGoogle Scholar

  • [36] Adams H. P. Jr., del Zoppo G., Alberts M. J., Bhatt D. L., Brass L., Furlan A. et al., Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists, Stroke, 2007, 38, 1655–1711 http://dx.doi.org/10.1161/STROKEAHA.107.181486CrossrefGoogle Scholar

  • [37] Demarin V., Lovrenčić-Huzjan A., Trkanjec Z., Vuković V., Vargek-Solter V., Šerić V. et al., Recommendations for stroke management 2006 update, Acta Clin. Croat., 2006, 45, 219–285 Google Scholar

  • [38] Fisher M., Stroke Therapy Academic Industry Roundtable. Recommendations for advancing development of acute stroke therapies: Stroke Therapy Academic Industry Roundtable 3, Stroke, 2003, 34, 1539–1546 http://dx.doi.org/10.1161/01.STR.0000072983.64326.53CrossrefGoogle Scholar

  • [39] Fisher M., Albers G. W., Donnan G. A., Furlan A. J., Grotta J. C., Kidwell C.S. et al., Stroke Therapy Academic Industry Roundtable IV. Enhancing the development and approval of acute stroke therapies: Stroke Therapy Academic Industry roundtable, Stroke, 2005, 36, 1808–1813 http://dx.doi.org/10.1161/01.STR.0000173403.60553.27CrossrefGoogle Scholar

  • [40] Fisher M., Hanley D. F., Howard G., Jauch E. C., Warach S., STAIR Group. Technology and Outcomes Recommendations From the STAIR V Meeting on Acute Stroke Trials, Stroke, 2007, 38, 245–248 http://dx.doi.org/10.1161/01.STR.0000255951.37434.aaCrossrefGoogle Scholar

  • [41] Saver J. L., Albers G. W., Dunn B., Johnston K. C., Fisher M., STAIR VI Consortium. Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials, Stroke, 2009, 40, 2594–2600 http://dx.doi.org/10.1161/STROKEAHA.109.552554CrossrefGoogle Scholar

  • [42] Albers G. W., Goldstein L. B., Hess D. C., Wechsler L. R., Furie K. L., Gorelick P. B. et al., STAIR VII Consortium. Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies, Stroke, 2011, 42, 2645–2650 http://dx.doi.org/10.1161/STROKEAHA.111.618850CrossrefGoogle Scholar

  • [43] Fisher M., New approaches to neuroprotective drug development, Stroke, 2011, 42(Suppl. 1), S24–27 http://dx.doi.org/10.1161/STROKEAHA.110.592394CrossrefGoogle Scholar

  • [44] Shuaib A., Hussain M. S., The past and future of neuroprotection in cerebral ischaemic stroke, Eur. Neurol., 2008, 59, 4–14 http://dx.doi.org/10.1159/000109254CrossrefGoogle Scholar

  • [45] Rother J., Neuroprotection does not work, Stroke, 2008, 39, 523–524 http://dx.doi.org/10.1161/STROKEAHA.107.494799CrossrefGoogle Scholar

  • [46] Ovbiagele B., Kidwell C. S., Starkman S., Saver J. L., Potential role of neuroprotective agents in the treatment of patients with acute ischemic stroke, Curr. Treat. Options Cardiovasc. Med., 2003, 5, 441–449 http://dx.doi.org/10.1007/s11936-003-0033-9CrossrefGoogle Scholar

  • [47] Danton G. H., Dietrich W. D., The search for neuroprotective strategies in stroke, Am. J. Neuroradiol., 2004, 25, 181–194 Google Scholar

  • [48] Segura T., Calleja S., Jordan J., Recommendationsand treatmentstrategiesfortheman- agement ofacuteischemicstroke, Expert Opin. Pharmaco., 2008, 9, 1071–1085 http://dx.doi.org/10.1517/14656566.9.7.1071CrossrefGoogle Scholar

  • [49] Saver J. F., Time is brain! — quantified, Stroke, 2006, 37, 263–266 http://dx.doi.org/10.1161/01.STR.0000196957.55928.abCrossrefGoogle Scholar

  • [50] Frendl A., Csiba L., Pharmacological and non-pharmacological recanalization strategies in acute ischemic stroke, Front. Neurol., 2011, 2, 32 Google Scholar

  • [51] Lutsep H. M., Clark W. M., Neuroprotective agents in stoke, emedicine. medscape.com, 2011, http://emedicine.medscape.com/article/1161422-overview Google Scholar

  • [52] The Internet Stroke Center. Stroke Trial registry, October 2011, http://www.strokecenter.org/trials/ Google Scholar

  • [53] Shuaib A., Bornstein N. M., Diener H. C., Dillon W., Fisher M., Hammer M. D. et al., SENTIS Trial Investigators. Partial aortic occlusion for cerebral perfusion augmentation: safety and efficacy of NeuroFlo in Acute Ischemic Stroke trial, Stroke, 2011, 42, 1680–1690 http://dx.doi.org/10.1161/STROKEAHA.110.609933CrossrefGoogle Scholar

  • [54] Stemer A. B., Huisa B. N., Zivin J. A., The evolution of transcranial laser therapy for acute ischemic stroke, including a pooled analysis of NEST-1 and NEST-2, Curr. Cardiol. Rep., 2010, 12, 29–33 http://dx.doi.org/10.1007/s11886-009-0071-3Google Scholar

  • [55] Carroll K. A. L., Chataway J., Understanding stroke: Patophysiology, presentation and investigation, Student BMJ, 2006, 14, 319–321 Google Scholar

  • [56] American Nimodipine Study Group 1992, Clinical trial of nimodipine in acute ischemic stroke. The American Nimodipine Study Group, Stroke, 1992, 23, 3–8 http://dx.doi.org/10.1161/01.STR.23.1.3CrossrefGoogle Scholar

  • [57] Kaste M., Fogelholm R., Erila T., Palomaki H., Murros K., Rissanen A. et al., A randomized, double- blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke, Stroke, 199, 25, 1348–1353 Google Scholar

  • [58] TRUST Study Group, Randomized, double-blind, placebo-controlled trial of nimodipine in acute stroke. Trust Study Group, Lancet, 1990, 336, 1205–1209 http://dx.doi.org/10.1016/0140-6736(90)92829-7CrossrefGoogle Scholar

  • [59] Wahlgren N. G., MacMahon D. G., DeKeyser J., Indrevik B., Ryman T., Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischemic stroke, Cerebrovasc. Dis., 1994, 4, 204–210 http://dx.doi.org/10.1159/000108483CrossrefGoogle Scholar

  • [60] Grotta J., Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole Ischemic Stroke Study Group, Stroke, 1997, 28, 2338–2346 http://dx.doi.org/10.1161/01.STR.28.12.2338CrossrefGoogle Scholar

  • [61] Davis S. M., Albers G. W., Diener H. C., Lees K. R., Norris J., Termination of acute stroke studies involving selfotel treatment. ASSIST Steering Committed, Lancet, 1997, 349, 32 http://dx.doi.org/10.1016/S0140-6736(05)62166-6CrossrefGoogle Scholar

  • [62] Lees K. R., Cerestat and other NMDA antagonists in ischemic stroke, Neurology, 1997, 49, S66–69 CrossrefGoogle Scholar

  • [63] Sacco R. L., De Rosa J. T., Halery E. C., Levin B., Ordronneau P., Phillips S. J. et al., Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial, JAMA, 2001, 285, 1719–1728 http://dx.doi.org/10.1001/jama.285.13.1719CrossrefGoogle Scholar

  • [64] Clark W. M., Raps E. C., Tong D. C., Kelly R. E., Cervene (Nalmefene) in acute ichemic stroke: final results of a phase III efficacy study. The Cervene Stroke Study Investigators, Stroke, 2000, 31, 1234–1239 http://dx.doi.org/10.1161/01.STR.31.6.1234CrossrefGoogle Scholar

  • [65] Lyden P., Shauaib A., Ng K., Levin K., Atkinson R. P., Rajput A. et al., Clomethiazole acute stroke study in ischemic stroke (CLASS-I): final results, Stroke, 2002, 33, 122–128 http://dx.doi.org/10.1161/hs0102.101478CrossrefGoogle Scholar

  • [66] Enlimomab Acute Stroke Trial Investigators, Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial, Neurology, 2001, 57, 1428–1434 Google Scholar

  • [67] Adams H. P., Effron M. B., Torner J., Dávalos A., Frayne J., Teal P. et al., Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESITT-II), Stroke, 2008, 39, 87–99 http://dx.doi.org/10.1161/STROKEAHA.106.476648CrossrefGoogle Scholar

  • [68] STIPAS Investigators, Safety study of tirilazad mesylate in patients with acute stroke (STIPAS), Stroke, 1994, 25, 418–423 http://dx.doi.org/10.1161/01.STR.25.2.418CrossrefGoogle Scholar

  • [69] Lyden P. D., Krieger D., Yenari M., Dietrich W. D., Therapeutic Hypothermia for acute stroke, Int. J. Stroke, 2006, 1, 9–19 http://dx.doi.org/10.1111/j.1747-4949.2005.00011.xCrossrefGoogle Scholar

  • [70] Clark W. M., Schim J. D., Kasner S. E., Victor S., Trafemin in acute ischemic stroke: results of phase II/III randomized efficacy study, Neurology, 2000, 54, A88 Google Scholar

About the article

Published Online: 2011-12-28

Published in Print: 2011-12-01


Citation Information: Translational Neuroscience, Volume 2, Issue 4, Pages 344–350, ISSN (Online) 2081-6936, ISSN (Print) 2081-3856, DOI: https://doi.org/10.2478/s13380-011-0041-2.

Export Citation

© 2011 Versita Warsaw. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Pandora Pound and Merel Ritskes-Hoitinga
Journal of Translational Medicine, 2020, Volume 18, Number 1

Comments (0)

Please log in or register to comment.
Log in